Replies to post #391144 on Innovation Pharmaceuticals Inc (IPIX)

[frenchbroad]

Thank you for this. Research continues to find all Brilacidin can do.

"Our ongoing studies with brilacidin, a host defense peptide (HDP)-based mimetic, have successfully demonstrated that brilacidin is able to interfere with viral integrity and exert an antiviral effect in vitro against candidate alphaviruses and bunyavirus. Furthermore, early indications support the potential of brilacidin to also act in an anti-inflammatory capacity by its impact on inflammatory cytokine expression."

"Ongoing studies are focused on obtaining the inhibition profile for EEEV in astrocytes and microglial cells."

"Additional ongoing studies are focused on assessment of brilacidin treatment on a broader array of inflammation-associated genes. Impact of brilacidin on maintenance of BBB integrity in the context of endothelial cells will also be investigated."

"Conclusions: The observations that we continue to make in experiments involving brilacidin in the context of acutely infectious viruses support the idea of brilacidin functioning in a broad-spectrum capacity as an antiviral compound."

[cellardwellar]

Thanks for posting thekid.

Conclusions: The observations that we continue to make in experiments involving brilacidin in the context of acutely infectious viruses support the idea of brilacidin functioning in a broad-spectrum capacity as an antiviral compound. Several lines of evidence suggest that brilacidin may affect virion integrity and hence impact viral entry, thus positioning it well as a broad-spectrum prophylactic countermeasure solution. The observations about anti-inflammatory activities indicate that intracellular events are also modulated by brilacidin treatment that exert a combined protective effect by decreasing viral and inflammatory load. Brilacidin has also undergone several clinical studies for multiple indications, using different routes of administration, and has a known safety profile in humans.

[sunspotter]

"support the idea of brilacidin functioning in a broad-spectrum capacity as an antiviral compound"

There are three things that mark this conclusion out as the triumph of hope over experience (or perhaps the triumph of hoping to get grants to do studies over honesty):

1) It's almost impossible to conceive that a substance that has to be administered by IV infusion on each of five days and therefore presents enormous logistical and economic challenges could be used as prophylaxis in exposed but asymptomatic and unconfirmed cases of possible viral infection

2) The side effect profile makes brilacidin a challenge to administer even therapeutically, let alone prophylactically (see the contraindications in the studies conducted so far). Severe hypertensive spikes and "mostly mild" peripheral neuropathy in asymptomatic people is not a risk/benefit ratio that looks very favorable, especially as the latter affects the majority of peole receiving brilacidin.

3) Then there's the small matter that in the only human study where brilacidin's anti-viral properties were tested, it failed its primary endpoint and showed no benefit over placebo.

I think most people who understand the field - including all of the business development folk at proper pharmaceutical companies - know this to be true.

The current noise about IPIX on social media is simply existing IPIX shareholders (and I suspect IPIX management's IRPs) trying to find unsuspecting victims onto whom to offload their own deeply underwater shares.

[loanranger]

Presenter Details, Submitter Details:
Affiliation:INDUSTRY
Status:Civilian, Other (Non-Government)
Name:Dr. Aarthi Narayanan
Primary Email:[e-mail]
Secondary Email:[e-mail]
Phone:[phone] ext. 2315
Organization:American Type Culture Collection
Manassas, VA 20110
https://www.atcc.org/

Associate Professor
George Mason University
May 2022 - Present 3 months

American Type Culture Collection Graphic
Director of Translational Research
American Type Culture Collection
Jun 2021 - May 2022 1 year
Virginia, United States

George Mason University
George Mason University
9 years 4 months
Associate Professor
Jun 2018 - Jun 2021 3 years 1 month

https://www.linkedin.com/in/aarthi-narayanan-ba4ba913

[CallMeCrazy]

My favorite line is in the conclusion:

Several lines of evidence suggest that brilacidin may affect virion integrity and hence impact viral entry, thus positioning it well as a broad-spectrum prophylactic countermeasure solution.

Long term I believe brilacidin will pan-out as a broad spectrum antiviral, but in the short term IPIX might be able to obtain an FDA-EUA for B-COVID as a prophylaxis for pre-exposure to COVID and for those who are early in their diagnosis of COVID-19 and at high risk of hospitalization or death. (Pre-exposure/post-exposure)

FDA initially gained EUA authority in 2004to facilitate access to drugs, biologics, and diagnostics needed for emergency use, as in the case of an anthrax attack, the emergence of a deadly virus such as Ebola or Zika, and other bioterrorism events. EUAs related to those conditions have not been terminated and remain in effect, largely for several in vitro diagnostics (IVDs) and added uses for some therapeutics.

Specific authority for FDA to approve EUAs related to SARS-CoV-2 was issued by the secretary of Health and Human Services (HHS) in February 2020 to facilitate the availability and use of qualifying treatments lacking full market approval. This authority does not expire automatically as with other Public Health Service emergency policies;

https://www.pharmtech.com/view/fda-and-industry-prepare-for-transition-from-emergency-use-authorizations

As subvariants become more transmissible and threaten to make COVID vaccinations ineffective, Brilacidin's MOA as a COVID prophylactic, along with the B's potential for a therapeutic EUA. I think, will be very favorably viewed by potential suitors.

The omicron BA.4 and BA.5 subvariants now make up 80% of Covid infections across the U.S., with BA.5 emerging as the dominant version of the virus. Fauci said BA.5 is more transmissible than past variants and it substantially evades the protective antibodies triggered by vaccines, but the shots are still generally protecting against severe disease. In other words, people who are fully vaccinated might get infected and have mild to moderate symptoms, but they are unlikely to be hospitalized and even more unlikely to die from Covid.

Fauci said BA.5 doesn’t appear to carry a great risk of severe disease compared with other omicron subvariants. But as cases increase due to its greater transmissibility, some people will end up in the hospital or ICU, he said.

https://www.cnbc.com/2022/07/12/covid-hospitalizations-have-doubled-since-may-as-omicron-bapoint5-sweeps-us-but-deaths-remain-low.html?fbclid=IwAR2de-W1-eWIiDx5BEu1Rxe9T9fxQxOzaQ9yEF6vDdAxkzVF01GI4wpQX5c

Regeneron (REGEN-COV) earned $2.59B in this space in 2021.